We are live on
!
Find out more
VCIM
Velan Capital Investment Management Portfolio holdings
AUM
$160M
1-Year Est. Return
517.12%
This Fund
S&P 500
This Quarter
Est. Return
+104.89%
1 Year Est. Return
+517.12%
3 Year Est. Return
+2,524.89%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$106M
AUM Growth
+$5.23M
(+5.2%)
Cap. Flow
-$14.9M
Cap. Flow
% of AUM
-13.95%
Top 10 Holdings %
Top 10 Hldgs %
68.17%
Holding
61
New
11
Increased
14
Reduced
5
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lantheus
LNTH
|
+$4.6M |
| 2 |
ABVX
Abivax
ABVX
|
+$3.95M |
| 3 |
Jasper Therapeutics
JSPR
|
+$3.74M |
| 4 |
ZOOZ
ZOOZ Strategy Ltd
ZOOZ
|
+$3.7M |
| 5 |
InspireMD
NSPR
|
+$3.01M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TRML
Tourmaline Bio
TRML
|
+$10.8M |
| 2 |
VRNA
Verona Pharma
VRNA
|
+$8.99M |
| 3 |
Zevra Therapeutics
ZVRA
|
+$6.3M |
| 4 |
Arvinas
ARVN
|
+$3.68M |
| 5 |
SCPH
scPharmaceuticals
SCPH
|
+$3.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.98% |
| 2 | Industrials | 4.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TRML
26
DELISTED
Tourmaline Bio
TRML
| $277K | 0.26% |
5,800
-388,089
| -99% | -$10.8M |
|
27
CytomX Therapeutics
CTMX
$760M
| $255K | 0.24% |
80,000
+5,000
| +7% | +$11.3K |
|
28
Protagonist Therapeutics
PTGX
$9.84B
| $246K | 0.23% |
3,700
| – | – |
|
29
Arrowhead Research
ARWR
$12.3B
| $224K | 0.21% |
+6,500
| New | +$143K |
|
30
Ovid Therapeutics
OVID
$489M
| $208K | 0.2% |
160,000
| – | – |
|
31
Gossamer Bio
GOSS
$86.8M
| $184K | 0.17% |
70,000
-5,000
| -7% | -$11K |
|
32
Alector
ALEC
$240M
| $163K | 0.15% |
55,000
| – | – |
|
33
Design Therapeutics
DSGN
$917M
| $151K | 0.14% |
20,000
| – | – |
|
|
TERN
34
DELISTED
Terns Pharmaceuticals
TERN
| $150K | 0.14% |
20,000
| – | – |
|
35
Nurix Therapeutics
NRIX
$2.76B
| $148K | 0.14% |
16,000
+6,000
| +60% | +$62.3K |
|
36
Erasca
ERAS
$6.45B
| $142K | 0.13% |
65,000
| – | – |
|
|
VTYX
37
DELISTED
Ventyx Biosciences
VTYX
| $124K | 0.12% |
40,000
| – | – |
|
38
Pyxis Oncology
PYXS
$201M
| $122K | 0.11% |
55,000
+15,000
| +38% | +$21.6K |
|
39
Immunome
IMNM
$3.17B
| $117K | 0.11% |
+10,000
| New | +$99.5K |
|
40
Precision BioSciences
DTIL
$205M
| $110K | 0.1% |
+20,000
| New | +$95.8K |
|
41
Wave Life Sciences
WVE
$1.03B
| $110K | 0.1% |
15,000
| – | – |
|
42
Geron
GERN
$1.01B
| $110K | 0.1% |
80,000
+10,000
| +14% | +$13.3K |
|
43
Larimar Therapeutics
LRMR
$454M
| $107K | 0.1% |
33,000
| – | – |
|
44
Context Therapeutics
CNTX
$43.2M
| $96.9K | 0.09% |
100,000
| – | – |
|
45
ProQR Therapeutics
PRQR
$262M
| $95.8K | 0.09% |
45,000
| – | – |
|
46
Replimune Group
REPL
$1.28B
| $83.8K | 0.08% |
20,000
-163,083
| -89% | -$1.04M |
|
47
Immix Biopharma
IMMX
$809M
| $73.2K | 0.07% |
35,000
+10,000
| +40% | +$24K |
|
48
Aclaris Therapeutics
ACRS
$860M
| $62.1K | 0.06% |
32,700
| – | – |
|
49
PMV Pharmaceuticals
PMVP
$67.2M
| $49K | 0.05% |
35,000
| – | – |
|
|
50
Arvinas
ARVN
$580M
| – | – |
-500,000
| Closed | -$3.68M |
|
Similar funds
BFAG
SLG
SMF
LCA
SGCM
RP
PCC
RCWM
Velan Capital Investment Management's Q3 2025 Portfolio in Review
As of Q3 2025, Velan Capital Investment Management held 61 positions worth $106M, up 5.2% from $101M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Velan Capital Investment Management withdrew a net $14.9M in Q3 2025, closing 12 positions and reducing 5 holdings. Its most notable exit was Verona Pharma, an estimated $8.99M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier, followed by Industrials.
Against the trend, Velan Capital Investment Management opened a new position in Lantheus worth $3.77M.
- Velan Capital Investment Management's largest Q3 2025 buy was Lantheus: 73,545 shares worth $3.77M.
- Velan Capital Investment Management added most to Jasper Therapeutics in Q3 2025, an estimated $3.74M increase.
- Velan Capital Investment Management's biggest Q3 2025 reduction was Tourmaline Bio, cutting an estimated $10.8M.
- Velan Capital Investment Management fully exited Verona Pharma in Q3 2025, selling an estimated $8.99M.
- Velan Capital Investment Management's ten largest holdings make up 68% of its $106M portfolio in Q3 2025.
- Velan Capital Investment Management opened 11 new positions and closed 12 in Q3 2025.
- Velan Capital Investment Management's portfolio value rose 5.2% quarter-over-quarter to $106M.
Based on Velan Capital Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.